A proportion of patients with lung cancer experience long-term clinical benefit with immune
checkpoint inhibitors (ICIs). However, most patients develop disease progression during …

Natural killer (NK) cell-based immunotherapies are attracting increasing interest in the field
of cancer treatment. Early clinical trials have shown promising outcomes, alongside …

Solid tumours display a limited response to immunotherapies. By contrast, haematological
malignancies exhibit significantly higher response rates to immunotherapies as compared …

Background Novel immunotherapy combination therapies have improved outcomes for
patients with hepatocellular carcinoma (HCC), but responses are limited to a subset of …

Cancer poses a significant global health burden, necessitating the widespread use of
chemotherapy and radiotherapy as conventional frontline interventions. Although targeted …

Abstract Introduction Cancer‐associated fibroblasts (CAFs) are correlated with the
immunotherapy response. However, the culprits that link CAFs to immunotherapy resistance …

Cancer immunotherapy is the great breakthrough in cancer treatment as it displayed
prolonged progression-free survival over conventional therapies, yet, to date, in only a …

Cancer is a complicated disease attributed to multifactorial changes, which causes
difficulties with treatment strategies. Various factors have been regarded as the main …

Immune checkpoint blockade (ICB) has rapidly transformed the treatment paradigm for
various cancer types. Multiple single or combinations of ICB treatments have been approved …

In the tumor microenvironment (TME), tumor-associated macrophages (TAMs) are the most
abundant immune cells, which act as a key regulator in tumorigenesis and progression …